SCHEDULE 13G/A: BlackRock Discloses 2.5% Passive Stake in Harvard Bioscience Inc.
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.5% in Harvard Bioscience Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 1,113,926 shares of Harvard Bioscience Inc. common stock.
- This ownership represents 2.5% of the total outstanding common stock of Harvard Bioscience Inc.
- BlackRock, Inc. holds sole voting power over 1,109,172 shares and sole dispositive power over 1,113,926 shares.
- No shared voting or dispositive power is reported.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Risks
- The reporting person certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates that BlackRock, a major institutional asset manager, holds a passive investment in Harvard Bioscience Inc. Such filings are standard disclosures for large investment firms when their beneficial ownership in a company's stock crosses certain thresholds (typically 5% for passive investors) or when there's a material change to a previously reported stake. It signifies a long-term, non-activist position.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. executed a new Power of Attorney, effective January 21, 2025, revoking a previous one dated April 30, 2023. This grants specific individuals the authority to execute and file documents related to ownership or control-person reporting requirements on behalf of BlackRock and its affiliates. | 2025-01-21 | Streamlines compliance with regulatory reporting requirements for BlackRock, Inc. by designating authorized signatories for SEC and other governmental filings. |
Stakeholder Impact
- Shareholders: Confirms a significant institutional investor, BlackRock, holds a passive stake in the company, which may be viewed as a vote of confidence in the company's long-term prospects, though the stake is below the threshold for active influence.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution for the Power of Attorney granted by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement. |
| 2025-07-17 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Harvard Bioscience Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.